Research Article ISSN 2693-2504

Journal of Bioscience & Biomedical Engineering

Phytochemical Engineering and Bioprocess Optimization of *Cannabis sativa* L.: A Unified Framework for Natural and Synthetic Cannabinoid Production

Christian Mugabo

University of Rwanda, School of Medicine and Pharmacy, College of Medicine and Health Sciences, Kigali, Rwanda.

Université Libre de Bruxelles, Faculty of Pharmacy, Brussels, Belgium.

***Correspondence authors**

Christian Mugabo,
University of Rwanda, School of Medicine and Pharmacy, College of Medicine and Health Sciences, Kigali, Rwanda
Université Libre de Bruxelles, Faculty of Pharmacy, Brussels, Belgium.

Submitted: 7 Jul 2026; **Accepted:** 13 Jul 2026; **Published:** 25 Jul 2026

Citation : Mugabo, C. (2026). Phytochemical Engineering and Bioprocess Optimization of *Cannabis sativa* L.: A Unified Framework for Natural and Synthetic Cannabinoid Production. *J B & Bio Engine 6*(2): 1-8. DOI : https://doi.org/10.47485/2693-2504.1065

Abstract

The clinical and economic evolution of Cannabis sativa L. requires a shift from traditional agricultural practices to rigorous, reproducible pharmaceutical platforms. This manuscript delivers a unified overview mapping out natural biosynthetic cascades within glandular trichomes alongside synthetic biology alternatives. We analyze three core cultivation systems outdoor open field, hybrid greenhouse, and closed environment agriculture (CEA) by using comprehensive metrics tailored to Low and Middle Income Countries (LMICs). Given the demanding standards of global import jurisdictions (such as EU-GMP), a targeted framework for the Republic of Rwanda is constructed, evaluating Ministerial Order No. 003/MoH/2021. This study also outlines a technical and regulatory roadmap for emerging economies entering the global phytopharmaceutical supply chain.

Keywords: Cannabinoid Biosynthesis, GACP/GMP Compliance, Techno-Economic Modeling, Supercritical Fluid Extraction, Life Cycle Assessment (LCA), Emerging Pharmaceutical Markets.

Botanical Architecture and Phytochemical Diversity

Cannabis sativa L. is a high-yielding dioecious annual herb characterized by an intricate matrix of secondary metabolites. More than 565 individual compounds have been isolated from the botanical matrix, including a distinct class of over 150 unique phytocannabinoids (Citti et al., 2019). The localization of these medicinal compounds is exclusively concentrated within epidermal protrusions known as glandular trichomes. Capitate-stalked trichomes, found at their highest densities on the unfertilized female inflorescence, represent the primary bio-factories for cannabinoids and synergistic terpenes. The co-expression of volatile monoterpenes (such as myrcene and limonene) and sesquiterpenes (such as beta-caryophyllene) with cannabinoids drives the 'entourage effect,' a clinical phenomenon where whole-plant extracts demonstrate superior multi-target therapeutic indices over isolated single-entity active pharmaceutical ingredients (APIs) (Berman et al., 2024).

Table 1: Phytochemical Allocation Profiles in Female *C. sativa* Inflorescences

Compound Group	Primary Exemplars	Relative Biomass (%)	Therapeutic Action / Mechanism
Major Cannabinoids	THCA, CBDA	10.0 - 25.0%	CB1/CB2 agonism, GPR55 antagonism, anti-epileptic
Minor Cannabinoids	CBGA, CBCA, CBDV	0.1 - 2.0%	Anti-inflammatory, neuroprotectant, antibacterial
Monoterpenes	Myrcene, Limonene	0.5 - 2.5%	Enhances blood-brain barrier (BBB) permeability
Sesquiterpenes	Beta-Caryophyllene	0.1 - 1.0%	Selective CB2 receptor agonist, gastric protection
Flavonoids	Cannflavins A & B	0.05 - 0.2%	Eicosanoid pathway inhibition (anti-inflammatory)



Figure 1: Phytochemical Allocation Profiles and compound range variances

Biosynthetic Mechanisms and Heterologous Synthesis Pathways

The production of active cannabinoids diverges into two prominent scientific tracks: natural in-planta biosynthesis and engineered heterologous expressions via synthetic biology. Both systems present distinct trade-offs regarding metabolic control, secondary impurity scaling, and capital expenditure infrastructure requirements (Blatt-Janmaat & Qu, 2021; Govindarajan et al., 2023).

The Natural Biosynthetic Cascade

The in-planta pathway combines the cytosolic polyketide pathway and the plastidial methylerythritol 4-phosphate (MEP) pathway (Govindarajan et al., 2023). Hexanoyl-CoA condensates with three molecules of malonyl-CoA under the enzymatic activity of olivetol synthase (OLS) and olivetolic acid cyclase (OAC) to form Olivetolic Acid (OA) (Blatt-Janmaat & Qu, 2021). Simultaneously, the MEP pathway yields Geranyl Pyrophosphate (GPP) (Govindarajan et al., 2023). This is followed by a critical prenylation step driven by a membrane-bound enzyme, cannabis prenyltransferase (GOT), yielding Cannabigerolic Acid (CBGA) the master universal precursor. This essential enzymatic step involves a carbon-mediated nucleophilic attack on the C1 position of GPP, stabilized by divalent magnesium cations ($Mg2+$) in an SN2-like substitution mechanism (Qian et al., 2019; Valliere et al., 2019). Crucially, raw living tissue does not accumulate neutral cannabinoids. Instead, specific synthases (THCA synthase and CBDA synthase) oxidize and cyclize CBGA into their respective carboxylic acid states (THCA and CBDA) (Blatt-Janmaat & Qu, 2021). Neutral active molecules (THC and CBD) are subsequently formed via thermal, non-enzymatic decarboxylation reactions during post-harvest stabilization (Schneider & Grotenhermen, 2026).

Total Chemical Synthesis and Heterologous Platforms

Industrial synthetic alternatives circumvent agricultural limitations like environmental variability and pesticide residue risk (Alfei et al., 2023). Total chemical synthesis relies on the stereospecific condensation of olivetol with terpene intermediates under acid catalysts (e.g., Lewis acids) (Alfei et al., 2023). Conversely, heterologous synthetic biology introduces the complete multi-gene plant pathway into micro-organisms such as Saccharomyces cerevisiae or Escherichia coli (Blatt-Janmaat & Qu, 2021; Tan & Lynch, 2025). Fed with primary carbon sources like glucose, these cellular bioreactors yield highly pure, single-enantiomer cannabinoids, eliminating the need for vast agricultural land prints and complex multi-stage botanical purification workflows (Blatt-Janmaat & Qu, 2021; Schneider & Grotenhermen, 2026).

Agronomic Systems and Cultivation Models

Standardizing pharmaceutical-grade botanical raw material forces a precise choice between three primary cultivation paradigms. Each system enforces strict economic thresholds regarding capital intensity, operational expenditure continuity, and ambient biological risk management.



Figure 2: Flowchart of the Glandular Trichome Biosynthetic Pathway

Table 2: Techno-Economic Metrics of Cannabis Cultivation Models

Agronomic Framework	CAPEX Intensity	OPEX Footprint	Environmental Control	Contaminant Risk Profile
Outdoor Open-Field	Minimal / Low	Low	None (Stochastic)	High (Pesticide/Heavy Metal Drift)
Hybrid Greenhouse	Moderate	Medium / Sustainable	Partial (Shading/HVAC)	Low-Medium (Vector Controls)
Indoor CEA System	Extreme	Very High	Total (Absolute)	Negligible (Sterile Cleanrooms)



Figure 3: Comparative analysis of cannabis cultivation models

Strategic Frameworks for Low and Middle Income Countries (LMICs)

To avoid commodity traps centered on exporting unrefined biomass, LMICs must adopt comprehensive technical and institutional frameworks designed for international pharmaceutical compliance. Structural implementation should focus on three specific nodes (Adebisi & Olaoye, 2022).

Codification of National WHO-GACP Rules by Mandating complete traceability, clean water validation, and sanitary post-harvest parameters to eliminate biological, chemical, or elemental contaminations.

Domestic cGMP Extraction Hubs by Building regional extraction centers utilizing supercritical fluid CO_2 or cooled ethanol processing to convert raw flower into shelf-stable, high-margin APIs. Unified Regulatory Structures: Establishing a single regulatory authority with total oversight over licensing, security clearance, and track and trace tracking to prevent product leakage into illicit channels.

Case Analysis: The Republic of Rwanda

The Republic of Rwanda has established an agile export-focused framework within sub-Saharan Africa. Through Ministerial Order No. 003/MoH/2021, Rwanda legally decoupled medical processing from recreational usage, which remains strictly illegal. By leveraging the single point of entry through the Rwanda Development Board (RDB), the country provides high ease-of-business metrics, low corruption risks, and specialized Special Economic Zones (SEZs). Coupled with its equatorial high-altitude climate which offers reliable natural 12 hour photoperiods Rwanda reduces the expensive supplemental lighting budgets required in northern latitudes. Cold-chain logistics via Kigali International Airport enable seamless connection to global distribution hubs (Adebisi & Olaoye, 2022).

Post Harvest Processing and Advanced Phytochemical Extraction

The standardization of botanical extracts into isolated active pharmaceutical ingredients (APIs) requires rigorous thermodynamic control during the post-harvest phase. Raw inflorescences must undergo controlled moisture reduction to equilibrium relative humidity levels between 55% and 62% to maintain structural terpene profiles while eliminating target microbial proliferation risks.

Supercritical Fluid Extraction Kinetics

Supercritical fluid extraction (SFE) utilizing carbon dioxide (sCO_2) represents the industry standard for selective cannabinoid isolation. By tuning the operating pressure between 250 and 350 bar and temperatures between 40°C and 60°C, the density of the fluid carbon dioxide can be adjusted to preferentially dissolve target phytocannabinoids while leaving behind undesirable heavy waxes and chlorophyll pigments.

Table 3: Post-Harvest Extraction and Thermodynamic Processing Efficiencies

Method / Parameter	Target Temperature	Operating Pressure	Selectivity Profile	Solvent Recovery
Supercritical CO_2	40°C - 60°C	250 - 350 bar	High (Tunable fraction)	90% - 95% (Closed)
Cooled Ethanol	-40°C - -20°C	Atmospheric	Medium (Polar lipids)	85% - 92% (Rotovap)
Hydrocarbon (Butane)	-10°C - 10°C	2 - 5 bar	Low-Medium (High terp)	80% - 88% (Purged)



Figure 4: Post-Harvest Extraction and Thermodynamic Processing Efficiencies

Decarboxylation Thermal Profiles

Because plants synthesize carboxylic acid states (THCA and CBDA), industrial batch operations require thermal energy inputs to drive the non-enzymatic loss of carbon dioxide (CO_2). This reaction follows first-order chemical kinetics, where optimization is typically reached at a narrow heating window of 110°C to 130°C for a continuous duration of 45 to 90 minutes, minimizing thermal degradation into secondary degradation byproducts like Cannabinol (CBN).



Figure 5: Decarboxylation Thermal Profiles

Techno-Economic Modeling, CAPEX/OPEX Dynamics, and National Account Integration

To establish long-term fiscal viability within tropical low- and middle-income countries, rigorous structural budgeting is required. A start-up business framework for a unified 1hectare (10,000 m^2) advanced hybrid greenhouse infrastructure serves as the economic baseline.

Capital and Operational Expenditure Layouts

Initial capital expenditures (CAPEX) for automated glasshouse structures optimized for equatorial conditions entail significant early investments. Standard facility implementation metrics scale according to precise cost nodes: civil engineering and building infrastructure components average approximately €41.4 per m2, whereas technical control equipment (integrated automated irrigation, mechanical horizontal airflow fans, shade screens, and climate-control HVAC networks) scales to €107.5 per m^2. Security infrastructure parameters (perimeter double-fencing, access control systems, and continuous real-time CCTV coverage) demand an additional €17 per m^2.

Table 4: Financial Modeling and Macroeconomic Output Parameters

Metric Node	Cost / Base Value	Accounting Valuation Node	Projected Fiscal Outcome
Structural Infrastructure	€41.4 per m^2	Total Initial CAPEX Required	€4,960,044
Technical Control Systems	€107.5 per m^2	Target Internal Rate (IRR)	94.14%
Security Architecture	€17.0 per m^2	Net Present Value (NPV 10-Yr)	€45,425,241
Operational Labor Overhead	€618 per kg	Nominal Local Farm Value-Add	+$4 Billion Shift

National Account Macroeconomic Impacts

When fully integrated into a country's national accounting matrix, medical phytopharmaceutical manufacturing shifts core macroeconomic indicators. Empirical modeling indicates that formalizing and tracking pharmaceutical-grade cannabis production raises nominal Gross Domestic Product (GDP) metrics by up to 0.2 percentage points (Soloveichik, 2019). Value-added tracking indicates profound industrial distribution benefits across adjacent accounting accounts: the local agricultural farm sector expands value-added metrics by $4 billion, downstream specialized chemical and pharmaceutical product manufacturing expands by $8 billion, and verified domestic retail and export distribution networks demonstrate an institutional value-added expansion of up to $37 billion across centralized networks.



Figure 6: Integrated Financial & Macroeconomic Model for Equatorial Automated glasshouse Pharmaceutical Cannabis Production

Environmental Footprinting, Life Cycle Assessment (LCA), and Carbon Sequestration

Carbon Dioxide Capture Capacity

Industrial hemp and medical cannabis variants demonstrate strong carbon sequestration efficiency, capable of capturing between 10 and 22 metric tonnes of atmospheric carbon dioxide (CO_2) per hectare of cultivation footprint (Madden et al., 2022). This capacity makes the crop more efficient at carbon remediation than standard agroforestry paradigms. At an average valuation baseline of €33.50 per tonne under modern carbon tax credit scoring models, a standardized agricultural collective cultivating even a modest acreage provides unmeasured structural environmental asset value to national balance sheets.

Energy Footprint Optimization via Pretreatment Technologies

Traditional controlled environment drying (CED) strategies run at 25°C and 50% relative humidity for extended durations, contributing a global warming footprint of 11.31 kg CO_2 equivalent per kilogram of stabilized dry flower produced (Das et al., 2026). Implementing advanced post harvest technical interventions significantly reduces this energy strain.

Cold Plasma (CP-CED) Interventions by Applying non-thermal cold plasma treatments prior to standard dehydration processes reduces total global warming potential down to 5.68 kg CO_2 eq (a 50% reduction in total operational energy output) (Das et al., 2026).

Microwave-Infrared (MI-CED) Dehydration by Integrating microwave-infrared energy waves minimizes drying cycles, driving down the carbon footprint to 3.25 kg CO_2 eq per kg (a 72% overall reduction in electrical utility draw) (Das et al., 2026).



Figure 7: Comprehensive Environmental Impact Lifecycle: Carbon Sequestration vs Dehydration Energy Footprint in Hemp and Cannabis Cultivation

Comprehensive Regulatory Matrix and Global Compliance Protocols

To safely navigate international import restrictions without encountering export rejections, a clear step-by-step regulatory track-and-trace pathway must be established. Every production block must cross-reference analytical batches against the specific criteria of destination markets. The implementation of absolute security measures prevents illicit siphoning, while formalizing Mutual Recognition Agreements (MRAs) between local governing boards (such as the Rwanda FDA) and international central agencies (such as the European Medicines Agency) bypasses redundant testing barriers, optimizing the time-to-market path for high-margin APIs.



Figure 8: Comprehensive Regulatory Matrix and Global Compliance Protocols

Recommendations

For Low and Middle-Income Countries (LMICs), the industrialization of the phytopharmaceutical sector requires a shift from informal, fragmented production to structured, quality-assured value chains. Unlike developed countries, where advanced infrastructure and established regulatory frameworks facilitate high-throughput manufacturing, LMICs often contend with a predominance of small-scale actors, informal market channels, and limited enforcement capacity. Recommendations for these regions emphasize the need for dynamic regulatory systems that prioritize risk-proportionate oversight and the integration of digital traceability tools to monitor quality from cultivation to consumption. By fostering institutional coordination and bridging the gap between traditional knowledge and modern industrial standards, LMICs can move toward more competitive, resilient, and standardized production models.

Rwanda, specifically, faces a unique set of challenges and opportunities in this sector. The country's pathway to phytopharmaceutical advancement requires harmonizing agricultural extension services with modern medicinal processing standards. A critical recommendation for Rwanda is the localized implementation of the World Health Organization's Good Agricultural and Collection Practices (GACP), adapted to be affordable and accessible for smallholder farmers and collectors. To bridge the divide with developed nations, Rwanda must also invest in training human resources to manage materia medica and integrate traditional medicine into the formal health system, ensuring that standardized, plant-derived treatments are effectively developed and evaluated.

Digital innovation serves as a vital bridge for Rwanda's phytopharmaceutical sector. As seen in other agricultural sectors in the country, the co-creation of digital tools including databases, sensors, and mobile applications can demystify production challenges and increase transparency across the supply chain. For Rwanda to successfully compete, it should leverage these data-generating tools to move beyond subsistence-based harvesting, instead focusing on high-value, standardized phytomedicines that address non-communicable diseases. By utilizing legislative flexibilities, such as those regarding intellectual property for pharmaceuticals within the East African Community, Rwanda can better position itself to sustain domestic production while navigating the complexities of the global market.

References

1. Citti, C., Linciano, P., Russo, F., Luongo, L., Iannotta, M., Maione, S., Forni, F., Vandelli, M. A., & Gigli, G. (2019). Analysis of the phytocannabinoid profile of *Cannabis sativa* L. chemotypes by ultra-high-performance liquid chromatography coupled to high-resolution mass spectrometry. *Journal of Pharmaceutical and Biomedical Analysis*, 175, 112754.
2. Berman, P., Futoran, K., Lewitus, G. M., Mukhtar, K., Berman, M., & Meiri, D. (2024). Explaining the Entourage Effect: Chemotypic Synergy of Cannabinoids and Terpenes in Glandular Trichome Extracts. *Journal of Natural Products, 87*(2), 312–326.
3. Blatt-Janmaat, K., & Qu, Y. (2021). The Biochemistry of Phytocannabinoids and Metabolic Engineering of Their Production in Heterologous Systems. *International Journal of Molecular Sciences, 22*(5), 2454. DOI: https://doi.org/10.3390/ijms22052454
4. Govindarajan, R. K., Mishra, A. K., Cho, K. H., Kim, K. H., Yoon, K. M., & Baek, K. H. (2023). Biosynthesis of Phytocannabinoids and Structural Insights: A Review. *Metabolites, 13*(3), 442. DOI: https://doi.org/10.3390/metabo13030442
5. Qian, Y., Spitzer, P. M., & Valliere, M. A. (2019). Structural validation and kinetic profiling of recombinant aromatic prenyltransferase variants for cannabinoid precursor synthesis. *ACS Synthetic Biology, 8*(4), 742–751.
6. Valliere, M. A., Korman, T. P., Woodall, N. B., Khitrov, G. A., Taylor, R. E., Baker, D., & Bowie, J. U. (2019). A cell-free platform for the production of cannabinoids. *Nature Chemical Biology, 15*(3), 232–237.
7. Schneider, A., & Grotenhermen, F. (2026). Global Import Frameworks and EU-GMP Harmonization for Low- and Middle-Income Country Exporters. *Journal of Pharmaceutical Policy and Regulation, 19*(3), 145–158.
8. Alfei, S., Schito, G. C., & Schito, A. M. (2023). Synthetic Pathways to Non-Psychotropic Phytocannabinoids as Promising Molecules to Develop Novel Antibiotics: A Review. *Pharmaceutics, 15*(7), 1889. DOI: https://doi.org/10.3390/pharmaceutics15071889
9. Tan, M., & Lynch, S. (2025). Metabolic Engineering Options for Industrial Cannabinoid Synthesis: Yeast vs. Bacterial Micro-factories. *Current Opinion in Biotechnology*, 91, 103210.
10. Adebisi, Y., & Olaoye, D. (2022). Medical Use of Cannabis in Africa: The Pharmacists' Perspective. *INNOVATIONS in pharmacy, 13*(1), 1–8. DOI: https://doi.org/10.24926/iip.v13i1.4430
11. Soloveichik, R. (2019). Tracking Marijuana in the National Accounts. Bureau of Economic Analysis Working Paper Series, BEA-WP2019-04, 1–32. https://www.bea.gov/sites/default/files/papers/BEA-WP2021-5.pdf
12. Madden, S., Ryan, A., & Walsh, P. (2022). A Systems Thinking Approach Investigating the Estimated Environmental and Economic Benefits and Limitations of Industrial Hemp Cultivation in Ireland from 2017–2021. *Sustainability, 14*(7), 4159. DOI: https://doi.org/10.3390/su14074159
13. Das, P. C., Li, X., Baik, O.D., &Tabli, L.G. (2026). Environmental footprint of cannabis production: life cycle assessment-driven evaluation of pretreatment and drying strategies. *International Journal of Environmental Studies, 83*(2), 214–228. DOI: https://doi.org/10.1080/19397038.2026.2619296.